These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 23917469)

  • 1. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
    Ferl GZ; Wu AM; DiStefano JJ
    Ann Biomed Eng; 2005 Nov; 33(11):1640-52. PubMed ID: 16341929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
    Chen Y; Balthasar JP
    AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
    Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
    Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
    Reusch J; Andersen JT; Rant U; Schlothauer T
    MAbs; 2024; 16(1):2361585. PubMed ID: 38849969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of FcRn binding assays to guide mAb development.
    Datta-Mannan A; Wroblewski VJ
    Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.